Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,068 across all filing types
Latest filing 2024-05-23 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vivesto AB for the period January 1 to March 31, 2024. It contains comprehensive financial statements, including net sales, operating results, earnings per share, and liquidity, as well as detailed management commentary on business operations, clinical trials, and future outlook. It is not an announcement of a report, but the report itself, and it contains substantive financial data. Q1 2024
2024-05-23 Swedish
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'Årsredovisning 2023' (Annual Report 2023) for the company Vivesto. It contains a comprehensive overview of the company's activities, management report (Förvaltningsberättelse), corporate governance (Bolagsstyrningsrapport), financial statements (Finansiella rapporter), notes (Noter), and auditor's report (Revisionsberättelse). This structure is characteristic of a full annual report. FY 2023
2024-04-23 Swedish
Kallelse till årsstämma i Vivesto AB
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Vivesto AB" (Notice of Annual General Meeting in Vivesto AB). It details the date, time, location, procedures for participation (including postal voting), agenda items (such as election of board members, auditor, and decisions on remuneration guidelines), and specific proposals related to the meeting. This content directly corresponds to the purpose of a notice for an Annual General Meeting (AGM). The Swedish term for AGM is 'årsstämma'. Therefore, the appropriate classification is AGM-R.
2024-04-23 Swedish
Notice of Annual General Meeting in Vivesto AB
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting in Vivesto AB" and details the date, time, location, procedures for attendance (including postal voting and proxy submission), and the proposed agenda items for the meeting. Key agenda items include the election of the Chairman, approval of the voting list, resolutions on the company's result, discharge from liability, determination of board/auditor numbers and fees, and resolutions on remuneration guidelines. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2024-04-23 English
Första patienten doserad i Vivestos kliniska studie med Paccal Vet
Regulatory Filings Classification · 98% confidence The document is a press release dated March 7, 2024, announcing that the first patient has been dosed in a clinical pilot study for a drug called Paccal Vet. It details the study progress, the drug's mechanism, and background information on the target disease (hemangiosarcoma in dogs). Crucially, the final section includes the statement: "Denna information är sådan information som Vivesto AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Vivesto AB is obliged to disclose pursuant to the EU's Market Abuse Regulation) and lists attached files. This structure strongly indicates a formal regulatory announcement intended for immediate public disclosure, rather than a comprehensive report (like 10-K or IR) or a transcript (CT). Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory filing/announcement category, RNS.
2024-03-07 Swedish
Vivesto doses first patient in its clinical Paccal Vet trial
Regulatory Filings Classification · 95% confidence The document announces a specific operational milestone: dosing the first patient in a clinical trial (Paccal Vet trial). It includes a date (March 7, 2024), quotes from the CEO, details about the study design, and concludes with a statement that the information is made public pursuant to the EU Market Abuse Regulation and includes an attachment link. This structure strongly suggests a press release or regulatory announcement regarding company progress, rather than a comprehensive financial report (10-K, IR) or a formal shareholder communication (DEF 14A, AGM-R). Since it is a general announcement of corporate activity that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category for a significant, non-financial regulatory update is Regulatory Filings (RNS), as it serves as a broad announcement mechanism.
2024-03-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.